FHTX · Foghorn Therapeutics Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.27M | - | $8.15M | $7.56M | $5.95M | - | $7.81M | $6.89M | $5.05M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $18.26M | - | $20.00M | $21.79M | $21.63M | - | $24.69M | $23.80M | $25.53M | - |
| SG&A | $6.58M | - | $6.65M | $6.86M | $7.24M | - | $6.97M | $7.33M | $7.71M | - |
| Total Operating Expenses | $24.84M | - | $26.65M | $28.65M | $28.86M | - | $31.66M | $33.52M | $33.24M | - |
| D&A | $238.0K | - | $900.0K | $900.0K | $827.0K | - | $700.0K | $800.0K | $835.0K | - |
| Operating Income | ($21.57M) | - | ($18.50M) | ($21.10M) | ($22.91M) | - | ($23.85M) | ($26.63M) | ($28.19M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | $0 | $0 | $0 | - |
| Net Income | ($19.88M) | - | ($15.85M) | ($17.94M) | ($18.83M) | - | ($19.12M) | ($22.98M) | ($25.02M) | - |
| EPS - Basic | ($0.29) | - | ($0.25) | ($0.28) | ($0.30) | - | ($0.31) | ($0.45) | ($0.59) | - |
| EPS - Diluted | ($0.29) | - | ($0.25) | ($0.28) | ($0.30) | - | ($0.31) | ($0.45) | ($0.59) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $87.66M | $80.88M | $89.33M | $72.57M | $61.03M | $55.45M | $57.68M | $138.95M | $79.25M | $80.34M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.32M | $4.27M | $3.21M | $3.32M | $4.07M | $3.79M | $3.45M | $4.81M | $5.63M | $6.26M |
| Current Assets | $188.06M | $163.24M | $184.12M | $203.84M | $225.42M | $249.60M | $271.23M | $289.62M | $211.52M | $240.18M |
| Total Assets | $222.17M | $198.10M | $204.96M | $226.24M | $258.69M | $283.98M | $308.37M | $328.58M | $255.00M | $285.92M |
| Current Liabilities | $64.40M | $59.74M | $85.09M | $77.79M | $71.31M | $66.99M | $56.82M | $50.87M | $52.06M | $58.44M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $298.57M | $306.60M | $294.62M | $302.89M | $320.34M | $329.51M | $336.66M | $342.91M | $352.49M | $363.11M |
| Stockholders' Equity | ($76.41M) | ($108.50M) | ($89.66M) | ($76.66M) | ($61.65M) | ($45.53M) | ($28.29M) | ($14.32M) | ($97.49M) | ($77.19M) |
| Retained Earnings | ($652.34M) | ($632.47M) | ($610.80M) | ($594.95M) | ($577.02M) | ($558.18M) | ($538.68M) | ($519.56M) | ($496.58M) | ($471.56M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($25.27M) | - | - | - | ($23.97M) | - | - | - | ($29.34M) | - |
| Investing Cash Flow | ($17.72M) | - | - | - | $29.40M | - | - | - | $27.09M | - |
| Financing Cash Flow | $49.77M | - | - | - | $139.0K | - | - | - | $1.17M | - |
| CapEx | $0 | - | - | - | $28.0K | - | - | - | $101.0K | - |
| Free Cash Flow | ($25.27M) | - | - | - | ($24.00M) | - | - | - | ($29.45M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -660.3% | - | -226.9% | -279.2% | -385.0% | - | -305.5% | -386.6% | -558.3% | - |
| EBITDA margin | -653.0% | - | -215.9% | -267.3% | -371.1% | - | -296.5% | -375.0% | -541.8% | - |
| Net margin | -608.4% | - | -194.4% | -237.3% | -316.4% | - | -244.9% | -333.6% | -495.4% | - |
| Free cash flow margin | -773.4% | - | - | - | -403.2% | - | - | - | -583.1% | - |
| FCF / Net income | 1.27 | - | - | - | 1.27 | - | - | - | 1.18 | - |
| R&D / Revenue | 558.9% | - | 245.3% | 288.4% | 363.3% | - | 316.2% | 345.5% | 505.6% | - |
| SG&A / Revenue | 201.4% | - | 81.6% | 90.8% | 121.6% | - | 89.3% | 106.3% | 152.7% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -8.9% | - | -7.7% | -7.9% | -7.3% | - | -6.2% | -7.0% | -9.8% | - |
| Return on equity | 26.0% | - | 17.7% | 23.4% | 30.5% | - | 67.6% | 160.4% | 25.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.92 | 2.73 | 2.16 | 2.62 | 3.16 | 3.73 | 4.77 | 5.69 | 4.06 | 4.11 |
| Quick ratio | 2.92 | 2.73 | 2.16 | 2.62 | 3.16 | 3.73 | 4.77 | 5.69 | 4.06 | 4.11 |
| Cash ratio | 1.36 | 1.35 | 1.05 | 0.93 | 0.86 | 0.83 | 1.02 | 2.73 | 1.52 | 1.37 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -2.91 | -1.83 | -2.29 | -2.95 | -4.20 | -6.24 | -10.90 | -22.94 | -2.62 | -3.70 |
| Liabilities / Assets | 1.34 | 1.55 | 1.44 | 1.34 | 1.24 | 1.16 | 1.09 | 1.04 | 1.38 | 1.27 |
| Efficiency | ||||||||||
| Asset turnover | 0.01 | - | 0.04 | 0.03 | 0.02 | - | 0.03 | 0.02 | 0.02 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 101.7x | - | 37.8x | 39.2x | 38.5x | - | 74.6x | 43.1x | 56.4x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -45.1% | - | 4.4% | 9.7% | 17.9% | - | -55.3% | 23.0% | -4.9% | - |
| Revenue CAGR (3y) | -14.9% | - | 7.1% | 19.0% | 14.9% | - | 475.3% | - | - | - |
| Revenue CAGR (5y) | - | - | 114.6% | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 5.8% | - | 22.4% | 20.8% | 18.7% | - | -39.6% | 16.9% | 15.4% | - |
| Net income growth (YoY) | -5.5% | - | 17.1% | 21.9% | 24.7% | - | -33.3% | 22.1% | 17.9% | - |
| EPS growth (YoY) | 3.3% | - | 19.4% | 37.8% | 49.2% | - | 8.8% | 35.7% | 19.2% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -5.3% | - | - | - | 18.5% | - | - | - | 7.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -23.9% | -138.3% | -217.0% | -435.3% | 36.8% | 41.0% | 50.7% | 71.0% | -296.5% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$30.91M totalThe Segment$30.91M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Foghorn Therapeutics Inc. against the 5 most active filers in the same SIC group.